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Sustained releaseIn this work, a novel concept is introduced in drug-eluting ﬁbres to ensure a good control of drug delivery
features and wide applicability to different bioactive compounds. Composite bioactive sutures based on ﬁbre
grade poly(ε-caprolactone) (PCL) and loaded with the anti-inﬂammatory drug Diclofenac (Dic) or a Dic
nanohybrid where the drug is intercalated in a synthetic hydrotalcite (Mg/Al hydroxycarbonate) (HT–Dic)
were developed. Fibres were prepared by melt-spinning at different PCL/HT–Dic/Dic ratios and analysed in
terms of morphology, mechanical properties and drug release features. Results emphasized that tensile proper-
ties of ﬁbres are clearly affected by Dic or HT–Dic addition, while the presence of knots has limited inﬂuence on
themechanical behaviour of the sutures. Release of Dic strongly depends on howDic is loaded in the ﬁbre (as free
or nanohybrid) whereas the combination of free Dic and HT–Dic can allow a further tuning of release proﬁle. In
vivo experiments show a reduction of inﬂammatory responses associatedwith Dic-loaded ﬁbers. Thus, a proof of
principle is provided for a novel class of bioactive sutures integrating advanced controlled-release technologies.niversity of Naples Federico II,© 2014 Elsevier B.V. All rights reserved.1. Introduction
Sutures are biomedical devices of natural or synthetic origin used to
held together tissues that have been separated due to surgery or trau-
matic injury. Despite the presence of different devices for wound
closure (staples, tapes and glues) available on the market, sutures are
the most widely diffused in the medical practice and have a market of
around 1.3 billion dollars a year [1]. Since a suture should fulﬁl a number
of requirements, unfortunately, no ideal product is available and the
surgeon generally operates a selection on the basis of availability and
familiarity [2,3]. Nevertheless, an appropriate suture should take into
account aspects such as mechanical properties, resorption rate, risk of
infection, and inﬂammatory reactions that may occur during wound
healing process. Over the years, new suture materials have been devel-
oped to better respond to particular surgical needs. Recently, the re-
search has switched toward a novel concept of medicated suture thatincludes a bioactive compound which can be released in a deﬁned
time frame and help tissue repair.
Research in this area, although being very attractive, has led to very
few products successfully entering the market [4–6]. The ﬁrst commer-
cial antimicrobial suture, a Polyglactin 910 suture loaded with triclosan,
a broad-spectrum antibacterial agent (Vicryl Plus®), was approved for
clinical uses by the US Food and Drug Administration (US FDA) since
2002 [7]. The basic concept in these sutures consists in coating a
preformed polymeric ﬁlament with a second biodegradable polymer
layer embedding triclosan with the aim to create a zone of inhibition
to the spread of bacteria and to exert a preventive action against the
possible infection of the surgical site [8]. Nowadays antimicrobial su-
tures are successfully used in a number of surgical procedures [7,
9–13]with a reduction ofwound site infection and consequent cost sav-
ing [14]. For all these reasons this treatment strategy was found to be
very promising and sutures coated with other drugs such as antithrom-
botic, analgesics, antineoplastic and antiproliferative agents are under
investigation [15].
Recently Lee et al. [16] have proposed a newmethod to obtainmed-
icated suture where a commercial suture is covered with a polymeric
sheet loaded with a pain relief drug. These sutures have been proven
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Fig. 1. The concept of anti-inﬂammatory ﬁbres developed in the study.
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6 days. Nevertheless, control of drug release rate is a critical factor to
design a bioactive suture in view of an optimized biological effect. For
this reason, more suitable strategies are needed to attain both efﬁcient
control over drug release rate and adequate mechanical properties. As
an alternative to coated ﬁbres, electrospun aligned ﬁbres have been
developed where different active agents are dispersed in a polymer to
give a matrix-like structure [17–20]. Unfortunately, ﬁbres show weak
mechanical properties and electrospinning is difﬁcult to scale-up,
making these systems difﬁcult to be applied.
A promising alternative is represented bymelt-spinning technology.
In this case, a polymermelt is forced through a spinneret capillary to ob-
tain ﬁbres with properties strongly related to the applied drawing ex-
tent. The application of this process, even if scalable up to industrial
level, is limited in the biomedical ﬁeld where the usual thermolability
of bioactive molecules as drugs and/or the relatively poor elongational
properties of biocompatible polymer melts, further worsened by incor-
poration of additives, may prevent a satisfactory drawing of ﬁbres
compromising their ultimate mechanical properties.
Among the strategies useful to control drug release from a
polymer matrix, the inclusion of lamellar structures opens new
opportunities to develop smart systems. Recently, magnesium
and aluminium hydroxycarbonates referred to as hydrotalcite-like
compounds (HT) intercalating bioactive molecules have been proposed
[21–24]. These systems consist of a layer of inorganic clays which,
under speciﬁc conditions, self-organize to form a bilayer. In particular
Mg/Al LDHs, where some Mg(II) cations are isomorphously replaced
by Al(III) cations, generate positive charges balanced by the presence
of counteranions located in the interlamellar region. The possibility of re-
placing these anions by simple ion-exchange procedures makes LDHs a
unique class of layered solids to be used as hosts of drugs bearing a neg-
ative charge. HTs have already been proven to be biocompatible and
some of them are already used in clinical practice as antiacids because
of their antipepsin activity [24]. In speciﬁc conditions, HT can intercalate
different anions or biologically active molecules such as anionic non-
steroidal anti-inﬂammatory drugs (NSAID) [25], antibiotics [26], up to
around 50% by weight and form organic–inorganic nanohybrids. De-
pending on drug features (solubility, molecular weight, afﬁnity to HT),
fast dissolution or sustained release of the drug can be accomplished as
a consequence of a de-intercalation process [27,28]. Furthermore, a
body of interest is growing on the development of novel composites
based on inorganic layeredmaterials and organic polymers. Recent stud-
ies report on the possibility to introduce organically-modiﬁed HT in dif-
ferent polymers as ﬁllers opening a new way to integration of bioactive
HT in polymeric ﬁlms, membranes or ﬁbres with different potential ap-
plications in industrial and biomedical ﬁeld [29–31]. In this context, on
the basis of an European patent owned by some participants to this
research [32], Sammartino et al. [31] incorporated nanohybrids contain-
ing theNSAIDDiclofenac (Dic) into poly(ε-caprolactone) (PCL)ﬁlms and
demonstrated effective control of drug release as compared to free drug
directly dispersed into the polymer.
Prompted by these considerations, in this paper we offer a proof of
principle on the possibility to obtain an anti-inﬂammatory sustained-
release biodegradable suture through the incorporation of a free drug
and/or a drug-HT nanohybrid in a thermoplastic polymer. To this
purpose a Dic-HT nanohybrid was incorporated in a ﬁbre of
poly(ε-caprolactone) (Fig. 1). The ﬁbrewas produced bymelt spinning
and characterized in terms of morphology, size, mechanical properties,
drug release and in vivo performance.
2. Materials and methods
2.1. Materials
A nanohybrid containing synthetic hydrotalcite and Diclofenac
(HT–Dic, [Mg2Al(OH)6](C14H10Cl2NO2) ∗ 2H2O,Mg/Al ratio 1.8, distancebetween layers = 23.6 Å, moisture 7.0%, Diclofenac loading = 59.6%)
was obtained from Prolabin & Tefarm (Italy). Diclofenac sodium (Dic)
was purchased from Farmalabor (Italy). Poly(ε-caprolactone), PCL,
used for this study (CAPA® 6800) was from Perstorp Corporation
(UK). HPLC-grade tetrahydrofuran (THF), acetonitrile and methanol,
analysis-grade acetone and dichloromethane were from Carlo Erba
(Italy). Synthetic hydrotalcite (HT, Mg6Al2(CO3)(OH16) ∗ 4H2O),
sodium chloride, potassium chloride, HPLC-grade triﬂuoroacetic acid
(TFA), sodium phosphate dibasic and potassium phosphate monobasic
(HPLC grade) were obtained from Sigma-Aldrich (USA). Distilled
ﬁltered (0.22 μm) water was employed.
2.2. Fibre production
Fibres were prepared through extrusion, drawing and subsequent
cold drawing to the ﬁnal diameter of approximately 300 μm. Prior to
the extrusion process, the components were separately sieved to obtain
a ﬁne powder (97% of the powder passed through a #140 sieve with a
mesh size of 106 μm according to Ph. Eur. 7th edition). The mean
diameter and size distribution of powders were determined by laser
light scattering (Coulter LS 100Q, USA). Particle size is expressed as
volumemeandiameter (μm)±SDof values collected from three different
batches. For Zeta potentialmeasurements, HT–Dicwas dispersed inwater
and analysed on a Zetasizer Nano Z (Malvern Instruments, UK).
The base materials were mixed in a HAAKE twin screw extruder
using a screw speed of 20 rpm and applying a temperature proﬁle
going from 60 °C, at feed zone, to 100 °C at the die. The ﬁlament was
cooled in stagnant air (at 23 °C) and collected with a take-up speed of
4 m/min. The as-spun ﬁbres (with a diameter of about 900 μm) were
drawn at 50 °C using a Conditioning Unit (DSMXplore, The Netherland)
to the ﬁnal diameter of about 300 μm (corresponding to a draw ratio of
9).
Different compositions of the ﬁbres, reported in Table 1, were select-
ed in order to investigate i) the effect of Dic intercalated in HT (Dic–HT)
as compared to free Dic (PCL/HT–Dic vs. PCL/Dic); ii) the inﬂuence of HT
in ﬁbres containing free Dic (PCL/HT/Dic vs. PCL/Dic) and iii) the
Table 1
Composition of PCL ﬁbres.
Fibre PCL (%) HT–Dic (%) HT (%) Dic (%) Dic
(mg/cm)
Diameter
(μm)
PCL/HT/Dic 75 – 8 17 0.095 264 ± 44
PCL/HT–Dic 82 18 – – 0.105 315 ± 30
PCL/HT–Dic/Dic 75 17 8 0.080 328 ± 67
PCL/Dic 82 – – 18 0.149 324 ± 21
302 O. Catanzano et al. / Materials Science and Engineering C 43 (2014) 300–309possible effect of free Dic in ﬁbres involving intercalated Dic (PCL/HT–
Dic vs. PCL/HT–Dic/Dic). We ﬁxed Dic loadings in the ﬁbre at 9 and
18% by wt in order to test the system at high loading where control of
drug release is generally poor.
2.3. Mechanical properties
Tensile properties of straight and simple knotted (according to Ph.
Eur. 7th edition) ﬁbres were measured using a universal testing
machine (Alpha Technologies mod. 2020) equipped with a 10 N load
cell. All tensile experiments were carried out at a strain rate of
300 mm/min, using a gage length of 150mm, at 23 °C. For each sample,
at least ﬁve specimens were analysed (if the ﬁbre broke in a clamp or
within 1 cm, the result was discarded and the test was repeated) and
average results are reported with their standard deviation. The mean
diameter was obtained after three measurements at points evenly
spaced along the suture using a 0.001 mm accuracy digital micrometer.Fig. 2. Properties of HT–Dic. A) Size distribution; B) SEMmicrograph; and C) release proﬁle of D
Na2HPO4 10 mM) and NaCl/KCl (NaCl 120 mM, KCl 2.7 mM) solution at pH 7.4 and 37 °C. ResMechanical properties of ﬁbres are expressed in terms of elastic
modulus, breaking load, breaking stress andpercent elongation at break.
2.4. Scanning electron microscopy/Energy Dispersive X-ray microanalysis
Suture shape and morphology were analysed by scanning electron
microscopy (SEM) (Quanta 200 FEG; FEI, USA). To analyse internal
structure, ﬁbre wire sections were prepared. The sample was included
into Tissue Tek® OCT (Sakura, Japan) and then cut into 40 μm slice
using a Tissue-Tek® Cryo3® Microtome/Cryostat (Sakura, Japan). The
sampleswere stuck on ametal stub and coatedwith gold under vacuum
evaporator for 90–120 s. Surface composition of the samples was inves-
tigated by Energy Dispersive X-ray spectroscopy (EDS) microanalysis
through a X-EDS detector (Oxford Inca Energy System 250 equipped
with INCAx-act LN2-free detector).
2.5. HPLC analysis of Diclofenac sodium
Dic analysis was carried out by RP-HPLC on a system consisting of a
FCV-10ALvp mixer, a LC-10ADvp pump equipped with a SIL-10ADvp
autoinjector, a SPD-10Avp UV–vis detector and a C-R6 integrator from
Shimadzu (Japan). The analysis was performed on a Luna 5μ C18
(250 × 4.6 mm) (Phenomenex, USA) at a ﬂow rate of 1.0 mL/min.
The injection volumewas 20 μL in all the experiments and the detection
wavelength ﬁxed at 238 nm.
For Dic quantitative analysis the mobile phase was acetonitrile/acid
water both modiﬁed with 0.1% TFA mixture in the ratio 70:30 v/v. Aic in PBS (NaCl 120 mM, KCl 2.7 mM, Na2HPO4 10mM), PBS2 (NaCl 240mM, KCl 5.4 mM,
ults are reported as mean ± SD of three measurements.
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Calibration curve was constructed by injecting solutions with concen-
trations in the range 0.3–30 μg/mL LOD was 0.08 μg/mL whereas QOD
was 0.26 μg/mL.2.6. In vitro release studies
In vitro release of Dic from the HT–Dic nanohybrid was evaluated by
dispersing 2mgof HT–Dic in 5mL of releasemediumat 37 °C. Three dif-
ferent release media were prepared: NaCl/KCl solution (NaCl 120 mM,
KCl 2.7 mM), Phosphate Buffer Saline (PBS, NaCl 120 mM, KCl 2.7 mM,
Na2HPO4 10 mM) and Phosphate Buffer Saline at double chloride con-
centrations (PBS2, NaCl 240 mM, KCl 5.4 mM, Na2HPO4 10 mM) both
at pH 7,4. At predetermined time intervals 1mL of supernatant was col-
lected after centrifugation (5000 rpm 15min 4 °C) and analysed by the
analytical method previously described for Dic quantiﬁcation.
The in vitro release of Dic was evaluated by immersing three ﬁbre
portions (3 cm) taken from different parts of extruded suture in 5 mL
of Phosphate Buffer Saline (PBS, NaCl 120 mM, KCl 2.7 mM e Na2HPO4
10 mM) at pH 7.4 and 37 °C under gentle shaking. Periodically 1 mL of
release medium was collected and replaced with the same volume of
fresh medium. The samples were analysed by the analytical methods
previously described and results are reported in terms of released Dic
percent.A
B
Fig. 3. SEM images of ﬁbre surface (A) and EDS analysis of PCL/HT–Dic ﬁFibremorphologywas evaluated also at the end of the release exper-
iment. To this purpose, ﬁbre was washed with water three times,
freeze-dried and then analysed by SEM.
2.7. In vivo experiments
Male CD1 mice (30–35 g) (Harlan, Italy) were purchased from
Harlan Italy (San Pietro al Natisone, UD, Italy) and housed in stainless
steel cages in a room kept at 22 ± 1 °C with a 12:12 h light/dark
cycle. The animals were acclimated to their environment for 1 week
and had ad libitum access to standard rodent chow pellets. All proce-
dures met the guidelines of the Italian Ministry of Health (D.L. no. 116
of January 27, 1992) and guidelines in the European Communities Coun-
cil (Directive of November 24, 1986, 86/609/ECC).
Mice were anesthetized with ketamine (100 mg/kg) and xylazine
(10 mg/kg), the back was shaved and scrubbed with betadine, and an
incision (4 cm in length, and 0.2 cm in deep) was made in the middle
using a number 12 blade. Five different sutures were used: 1) PCL
suture; 2) PCL/HT/Dic, 3) PCL/Dic; 4) PCL/HT–Dic/Dic; and 5) PCL/
HT–Dic. The wounds were closed with three sutures for sub-
cutaneous and four sutures for cutaneous tissues. After 3 days from sur-
gery, mice were killed and cutaneous and sub-cutaneous tissues were
removed. The samples were ﬁxed in 10% neutral buffered formalin,
then processed and embedded in parafﬁn, according to standardized
protocol. Sections of 4 μmwere stained with haematoxylin and eosin.Mean (%) Standard Deviation 
C 66.74 0.20 
O 26.16 0.18 
Mg 2.06 0.21 
Al 1.21 0.07 
Cl 3.83 0.10 
bre surface (B). The sample is representative of outer ﬁbre surface.
304 O. Catanzano et al. / Materials Science and Engineering C 43 (2014) 300–309Two histological parameters were evaluated in each sample: inﬂam-
matory inﬁltrate and granulation tissue. They were graded according to
semi quantitative score as:
þ ¼ weak inflammatory infiltrate=low amount of granulation tissueFig. 5. Elastic modulus of ﬁbres with different compositions. Results are the mean of ﬁve
measurements, error bars are standard deviations.þþ ¼ moderate inflammatory infiltrate=moderate amount of granulation tissue
þþþ ¼ intense inflammatory infiltrate=intense amount of granulation tissue:
3. Results and discussion
3.1. Fibre extrusion and morphology
The aim of this work was to develop an anti-inﬂammatory drug-
eluting synthetic suture and to test its effects in vivo. Modulation of
drug delivery rate was considered as a key parameter to achieve regional
prolonged release and to promote healing process. We focused on melt-
spinning technique to produce polymeric ﬁbres with regular circular
cross section since it couples good versatility, fast industrial scale-up
and does not require organic solvents. Nevertheless, melt-spinning per-
fectly ﬁts loading of very hydrophilic drugs in water-insoluble polymers
such as PCL ensuring high entrapment efﬁciency. After characterization,
the HT–Dic nanohybrid was included in PCL ﬁbres, which were then
drawn to obtain suitable diameter and fully investigated.
Properties of HT–Dic nanohybrid are reported in Fig. 2. The size
distribution curve showed a monomodal trend and a HT–Dic mean
particle diameter of 2.4 ± 0.2 μm. Surface charge of the nanohybridFig. 4. SEM images of ﬁbre section. The samplewas slightly negative. SEM analysis conﬁrmed the size and the HT
lamellar structure.
The release proﬁle of Dic from the HT–Dic nanohybrid was evalu-
ated in physiologically-simulated conditions. HT consists of layers of
magnesium hydroxide, with aluminium isomorphically substituted
to give a net positive charge inside the layers that is balanced by in-
terlayer hydrated Dic anions. To achieve drug release, the presence ofis representative of other inner sections.
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the nanohybrid is needed. Since in a physiological environment the
most available anions are chlorines and phosphates, Dic release
fromHT–Dic was tested in media at different chloride and phosphate
concentrations (Fig. 2c). As expected for this type of system, release
rate was strongly inﬂuenced by the ionic composition of the medi-
um. PBS ensured a complete release of Dic from the intercalation
product and was selected for further release experiments on ﬁbres.
Biodegradable PCL ﬁbres with different compositions were proc-
essed by a two-step melt-spinning method (melt extrusion and hot
draw) (Table 1). Melt spinning has proven to be a robust method forthe production of several biomedical devices and it has been found to
be useful in the pharmaceutical industry as well [33]. Since many
years this technique has been already used for the industrial production
of sutures because it is an economical process with reduced production
time, few processing steps, and offering the possibilities to work in con-
tinuous. Furthermore, the capacity of melt extrusion to disperse differ-
ent active pharmaceutical ingredients in a matrix at molecular level
(forming solid solutions) has been seen as a possible strategy to increase
solubility and bioavailability of water-insoluble compounds [34,35].
One disadvantage of this production method is the necessity to operate
at high temperature in order tomelt the polymerwhilemost drugsmay
degrade at high temperature. In the present case, RP-HPLC qualitative
analysis of Dic extracted from the PCL/HT–Dic after extrusion conﬁrmed
that the production method does not affect drug stability (Supplemen-
tarymaterial S1). Nevertheless, this strategy of drug loading throughHT
can be of beneﬁt for those molecules with poor thermal stability as well
as drugs undergoing polymorphism in order tomaintain their chemical–
physical integrity.
After extrusion,ﬁbreswere analysed by scanning electronmicrosco-
py (SEM) to evaluate size and surface morphology (Fig. 3). In details, as
spun ﬁbre of PCL formed at 100 °C die temperature showed extruding
lines on the surface (Fig. 3a), likely due to polymer curing in the applied
processing conditions. Nevertheless, the presence of some particles on
the surface of the ﬁbres containing HT or HT–Dic was observed. To
investigate the nature of these particles, ﬁbre surface was analysed by
Energy Dispersive X-ray spectroscopy (EDS). Particles were composed
mainly by magnesium and aluminium, thereby suggesting that
HT–Dic particles also locate on the ﬁlament surface during processing
(Fig. 3b).
To evaluate the inner morphology of the ﬁbres, SEM images on ﬁbre
sections were taken (Fig. 4). All the ﬁbres had round cross-sectional
geometry andnon-porousmorphology,with an average diameter around
0.3 mm comparable with those measured by a calibre (Table 1). Micro-
graphs indicated a rather homogeneous dispersion of included compo-
nents with the presence of small internal voids due to a decrease of
feeding load during extrusion.
3.2. Mechanical properties
Given that the use of sutures strongly depends on mechanical
properties, their strength is the most frequently reported parameter
Fig. 8. SEM images of ﬁbres after 70 days of incubation in PBS (10 mM) at pH 7.4 and 37 °C.
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tissue strength [36] and for this reason the selection of proper suture
depends also from the tissue involved. Furthermore, tensile proper-
ties of sutures are important when making a knot. If the material is
too weak and the knotting force is stronger than tensile strength of
suture material, suture can easily break while tightening the knot
[37,38].
Results of tensile tests performed onmelt-spun straight and knotted
ﬁlaments are shown in Figs. 5 and 6.
The elastic modulus data (Fig. 5) indicated that the inclusion of
particulate components decreased the stiffness of the ﬁbre with respect
to pure PCL. In particular, the addition of HT–Dic caused a reduction of
tensile modulus from 1400 MPa to about 1100 MPa (−25%) while the
inclusion of Dic caused a remarkable reduction of the modulus up to
about 480 MPa (corresponding to−66%). Systems including both Dic
and HT as well as Dic and HT–Dic also showed a signiﬁcant decrease
in modulus.
Tensile properties (breaking stress and elongation at break) of
straight and knotted ﬁbres are shown in Fig. 6. Data indicated that with-
in experimental errors:
- the knotted ﬁbres had the same breaking stress and the same elon-
gation at break of straight ﬁbres thus indicating that the knot does
not represent a weakness to the ﬁbre;- composite ﬁbres showed a three-fold decrease with respect to pure
PCL ﬁbres in breaking stress;
- ﬁbres containing HT–Dic showed a fragile behaviour with elonga-
tions at break around 20% (other systems being around 70%) and a
tenacity in the range 10–17 MJ/m [3] (other systems being around
70 MJ/m3).
The effect of knotting on the strength of various sutures was studied
by Kim et al. [38], who concluded that the knotting of a suture reduced
its tensile strength. In thepresent case the knots do only have amarginal
inﬂuence on the mechanical behaviour of the ﬁbres, and this is an
advantage for their use in slow-healing tissues (skin, fascia and
tendons).
3.3. In vitro release and degradation
The release proﬁle of Dic from ﬁbres was assessed in PBS at pH 7.4
and 37 °C, simulating physiological conditions (Fig. 7). In all the sam-
ples, an initial burst of Dic was observed. The control ﬁbre containing
freeHTandDic (PCL/HT/Dic, Dic content 0.095mg/cm) completely elut-
ed its Dic content in around 14 days, thus showing a poor control over
release rate. The ﬁbres containing HT–Dic (PCL/HT–Dic, Dic content
0.105 mg/cm) showed a nicely shaped release proﬁle reaching com-
plete Dic release after 55 days. In the ﬁbre containing both HT–Dic
Table 2
Inﬂammatory inﬁltrate and granulation tissue in specimens.
Inﬂammatory inﬁltrate Granulation tissue
Fibre Cutaneous
tissue
Sub-cutaneous
tissue
Cutaneous
tissue
Sub-cutaneous
tissue
PCL/Dic ++ ++/+++ – –
PCL/HT/Dic +/− + – –
PCL/HT–Dic + ++ – +
PCL/HT–Dic/Dic + ++ – –
PCL +/++ +/++ – –
+ = weak inﬂammatory inﬁltrate/low amount of granulation tissue.
++ = moderate inﬂammatory inﬁltrate/moderate amount of granulation tissue.
+++ = intense inﬂammatory inﬁltrate/intense amount of granulation tissue.
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release rate was again well modulated besides the presence of free
Dic. Dic amount released from PCL ﬁbre (PCL/Dic, Dic content
0.0149 mg/cm) was higher than for the other ﬁbres due to a higher
Dic loading. After 70 days Dic was still released in native form indicating
the protective effect of PCL and HT on its chemical structureFig. 9. Haematoxylin and eosin-stained sections of cutaneous and sub-cutaneous tissues from
ﬁbroblasts.(Supplementary material S1). These data suggest that a ﬁne tuning of
release proﬁles can be accomplished playing on reciprocal HT–Dic/Dic
ratio and optimal amount of released Dic may be selected according to
the therapeutic needs.
In order to evaluate themode of degradation, ﬁbremorphology was
analysed after 70 days of release in PBS at pH 7.4 at 37 °C (Fig. 8).
Surfacemodiﬁcation of the ﬁbre, likely due to slow polymer progressive
degradation, was observed without the occurrence of fractures. As
expected, the extent of polymer degradation was very limited and con-
ﬁned to the surface, conﬁrming that this kind of system behavesmainly
as a surface eroding system. Nevertheless, surface degradation of PCL
determined the outcrop on the surface of HT and HT–Dic as shown by
EDS analysis. This phenomenon was particularly evident in the PCL/
HT/Dic ﬁbre.
Drug release kinetics from a polymer matrix mainly depends
on three distinct steps; (a) liquid penetration into the matrix,
(b) dissolution and, (c) diffusion of drug, which may be the rate deter-
mining step for drug release. Progressive matrix degradation can affect
drug diffusion rate along time. The degradation mode observed for
PCL ﬁbres suggests that Dic release is predominantly controlled bymice at suture site, after 3 days from surgery. Arrows indicate small blood vessels and
308 O. Catanzano et al. / Materials Science and Engineering C 43 (2014) 300–309drug dissolution and diffusion in the polymer matrix. Indeed both Dic
and HTmay affect the PCL structure and, thus, the release mechanisms.
In the case of PCL/Dic, drug diffusion in the rubbery PCL phase as well
as through polymer mesopores is the prevailing mechanism. In par-
ticular, except that the crystallinity of the matrix is not signiﬁcantly
altered by additives, Dic could partially bind to PCL with effects of
plasticization conﬁrmed in the case of the PCL/Dic ﬁbre showing
stiffness lower than that of pure PCL. This hypothesis also allows to
explain the rapid diffusion of drug shown by the PCL/Dic ﬁlaments
compared to other ones. When the ﬁbre contains HT–Dic nanohybrid,
Dic needs to diffuse out of the lamellar structure and then through the
polymer matrix, which adds a supplementary release step contributing
to the overall release proﬁle. In fact, HT can favour an increase of the
tortuosity and, consequently, of the diffusion length with effects that
dependon both the content and the distribution of thisﬁllerwith signif-
icant complexity.
Overall, these results suggest that direct incorporation of Dic in PCL
ﬁbres controls drug release rate but results in poor suture mechanical
properties. On the other side, incorporation of HT–Dic nanohybrids in
the ﬁbres allows to control effectively both release proﬁle andmechan-
ical properties.
3.4. In vivo effects
To assess in vivo anti-inﬂammatory effect, ﬁbres were employed
to close a traumatic wound in mice. Two histological parameters
were evaluated in each sample: inﬂammatory inﬁltrate and granulation
tissue (Table 2).
Sections of cutaneous and sub-cutaneous tissue at suture site
were stained by haematoxylin and eosin (Fig. 9). In samples containing
PCL/Dic an inﬂammatory inﬁltrate variable from moderate to intense
was observed, especially at the level of the sub-cutaneous tissue, with-
out formation of granulation tissue. In all the other specimens no varia-
tions in the inﬂammatory responsewas observed, except for PCL/HT/Dic
where this reaction was found to be less intense. It is worth of note that
the presence of granulation tissue was observed only in the sub-
cutaneous tissue of PCL/HT–Dic sample. For PCL ﬁbre, the inﬂammatory
response appeared to be less intense, again without the formation of
granulation tissue. Regardless of the surgical site, the inﬂammatory
reaction in the injured tissue reduces the damage, removes damaged
tissue components and stimulates the deposition of extracellular ma-
trix, inducing angiogenesis. Therefore the observation that a granulation
tissue is present can be related to an expression of a more effective and
early reparative process in progress.
Sustained Dic release may represent a clinically relevant therapeutic
modality. In fact, besides anti-inﬂammatory effect, sustained Dic release
can have an impact also in the management of postoperative pain, thus
minimizing the dose ofmedications to lessen side effects while still pro-
viding adequate analgesia. To date, perioperative administration of a
single local dose of nonsteroidal anti-inﬂammatory drugs has shown in-
conclusive efﬁcacy [39]. Rather than a single bolus, Lavand'homme et al.
[40] found that continuous intrawound infusion of Dic demonstrated a
greater opioid-sparing effect and better postoperative analgesia than
the same dose administered as an intermittent intravenous bolus.
Thus, Dic-eluting sutures can combine delivery concepts to a biomedical
device to exert both effective control of inﬂammatory phase and allevi-
ation of post-operative pain.
4. Conclusions
In summary, we have developed a drug-eluting anti-inﬂammatory
suture that could have the dual function of closing the site of wound
excision while providing sustained localized delivery of Diclofenac.
Themelt spun ﬁbre containingHT–Dic nanohybrid has shown a homog-
enous distribution of ﬁller, good mechanical properties, tuneable
release rate as a function of composition and in vivo activity thatsuggests its use in surgical practice. Overall, the strategy proposed is of
great potential and versatility sincemelt-spinning is a simple and repro-
ducible process that can be scaled-up at industrial level. Nevertheless,
control of ﬁbre properties by nanohybrid should help to extend the ap-
plicability of this concept to other bioactive drugs.
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